271 research outputs found
Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization
Background: Multiple myeloma (MM) is an incurable hematological disorder characterized by the accumulation of malignant plasma cells within the bone marrow (BM). The clinical heterogeneity of MM is dictated by the cytogenetic aberrations present in the clonal plasma cells (PCs). Cytogenetic studies in MM are hampered by the hypoproliferative nature of plasma cells in MM. Therefore, fluorescence in situ hybridization (FISH) analysis combined with magnetic-activated cell sorting (MACS) is an attractive alternative for evaluation of numerical and structural chromosomal changes in MM. Methods: Interphase FISH studies with three different specific probes for the regions containing 13q14.3 (D13S319), 14q32 (IGHC/IGHV) and 1q12(CEP1 ) were performed in 48 MM patients. Interphase FISH studies with LSI IGH/CCND1, LSI IGH/FGFR3, and LSI IGH/MAF probes were used to detect t(11;14)(q13;q32), t(4;14)(p16;q32), and t(14;16)(q32;q23) in patients with 14q32 rearrangement. Results: Molecular cytogenetic aberrations were found in 40 (83.3%) of the 48 MM patients. 13 patients (27.1%) simultaneously had 13q deletion/monosomy 13 [del(13q14)], illegitimate IGH rearrangement and chromosome 1 abnormality. Del(13q14) was detected in 21 cases (43.7%), and illegitimate IGH rearrangements in 29 (60.4%) including 6 with t(11;14) and 5 with t(4;14). None of 9 patients with illegitimate IGH rearrangements and without t(11;14) or t(4;14) we detected had t(14;16) (q32;q23). 24 of the 48 MM patients (50%) had chromosome 1 abnormalities. Among 21 patients with del(13q14), 15 patients had Amp1q12;16 had IgH rearrangements. Whereas, among 27 cases without del(13q14), 8 had Amp1q12; 13 had IgH rearrangements. There was a strong association between del(13q14) and Amp1q12(c2 = 8.26, Ρ < 0.01), and between del(13q14) and IgH rearrangement(c2 = 3.88, p < 0.05). Conclusion: 13q deletion/monosomy 13, IGH rearrangement and chromosome 1 abnormality are frequent in MM. They are not randomly distributed, but strongly interconnected. Interphase FISH technique combined with MACS using CD138-specific antibody is a highly sensitive technique at detecting molecular cytogenetic aberrations in MM.ΠΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠ΅: ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½Π°Ρ ΠΌΠΈΠ΅Π»ΠΎΠΌΠ° (MM) β Π½Π΅ΠΈΠ·Π»Π΅ΡΠΈΠΌΠΎΠ΅ Π³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΈΡΡΡΡΠ΅Π΅ΡΡ
Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½ΠΈΠ΅ΠΌ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
ΠΏΠ»Π°Π·ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΊΠ»Π΅ΡΠΎΠΊ Π² ΠΊΠΎΡΡΠ½ΠΎΠΌ ΠΌΠΎΠ·Π³Π΅ (ΠM). ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΠΎΡΡΡ MM ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅ΡΡΡ
ΡΠΈΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π°Π±Π΅ΡΡΠ°ΡΠΈΡΠΌΠΈ, ΠΏΡΠΈΡΡΡΡΡΠ²ΡΡΡΠΈΠΌΠΈ Π² ΠΊΠ»ΠΎΠ½Π΅ ΠΏΠ»Π°Π·ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΊΠ»Π΅ΡΠΎΠΊ (ΠΠ). Π¦ΠΈΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ
MM ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½Ρ Π³ΠΈΠΏΠΎΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠ²Π½ΡΠΌΠΈ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΠΌΠΈ ΠΠ. Π ΡΠ²ΡΠ·ΠΈ Ρ ΡΡΠΈΠΌ ΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠ½Π°Ρ Π³ΠΈΠ±ΡΠΈΠ΄ΠΈΠ·Π°ΡΠΈΡ in situ (FISH)
Π² ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Ρ ΡΠΎΡΡΠΈΡΠΎΠ²ΠΊΠΎΠΉ ΠΊΠ»Π΅ΡΠΎΠΊ, Π°ΠΊΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΌΠ°Π³Π½ΠΈΡΠ½ΡΠΌΠΈ ΠΏΠΎΠ»ΡΠΌΠΈ (MACS) ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅ΡΡΡ Π΄ΠΎΡΡΠΎΠΉΠ½ΠΎΠΉ Π°Π»ΡΡΠ΅ΡΠ½Π°ΡΠΈΠ²ΠΎΠΉ
ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΠΎΡΠ΅ΡΠ½ΡΡ
ΠΈ ΡΡΡΡΠΊΡΡΡΠ½ΡΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ Ρ
ΡΠΎΠΌΠΎΡΠΎΠΌ ΠΏΡΠΈ MM. ΠΠ΅ΡΠΎΠ΄Ρ: ΠΈΠ½ΡΠ΅ΡΡΠ°Π·Π½ΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ
FISH Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΡΠ΅Ρ
ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π·ΠΎΠ½Π΄ΠΎΠ² Π΄Π»Ρ ΡΡΠ°ΡΡΠΊΠΎΠ², ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΡ
13q14.3 (D13S319), 14q32
(IGHC/IGHV) ΠΈ 1q12(CEP1), ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Ρ 48 Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ MM. ΠΠ½ΡΠ΅ΡΡΠ°Π·Π½ΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ FISH Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ
Π·ΠΎΠ½Π΄ΠΎΠ² LSI IGH/CCND1, LSI IGH/FGFR3 ΠΈ LSI IGH/MAF ΠΏΡΠΈΠΌΠ΅Π½ΡΠ»ΠΈ Π΄Π»Ρ Π΄Π΅ΡΠ΅ΠΊΡΠΈΠΈ t(11;14)(q13;q32), t(4;14)(p16;q32), ΠΈ
t(14;16)(q32;q23) Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΏΠ΅ΡΠ΅ΡΡΡΠΎΠΉΠΊΠΎΠΉ 14q32. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΠ΅ ΡΠΈΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π°Π±Π΅ΡΡΠ°ΡΠΈΠΈ Π²ΡΡΠ²Π»ΡΠ»ΠΈ Ρ
40 (83,3%) ΠΈΠ· 48 Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ MM. Π£ 13 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (27,1%) ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Ρ 13q Π΄Π΅Π»Π΅ΡΠΈΡ/ΠΌΠΎΠ½ΠΎΡΠΎΠΌΠΈΡ 13 [del(13q14)],
Π°Π½ΠΎΠΌΠ°Π»ΡΠ½Π°Ρ ΠΏΠ΅ΡΠ΅ΡΡΡΠΎΠΉΠΊΠ° IGH ΠΈ Π°Π½ΠΎΠΌΠ°Π»ΠΈΡ Ρ
ΡΠΎΠΌΠΎΡΠΎΠΌΡ 1. Del(13q14) Π΄Π΅ΡΠ΅ΠΊΡΠΈΡΠΎΠ²Π°Π»ΠΈ Π² 21 ΡΠ»ΡΡΠ°Π΅ (43,7%), Π° Π°Π½ΠΎΠΌΠ°Π»ΡΠ½ΡΠ΅
ΠΏΠ΅ΡΠ΅ΡΡΡΠΎΠΉΠΊΠΈ IGH β Π² 29 (60,4%), Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ Ρ 6 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ t(11;14) ΠΈ 5 Ρ t(4;14). ΠΠΈ Ρ ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΈΠ· 9 Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ Π°Π½ΠΎΠΌΠ°Π»ΡΠ½ΡΠΌΠΈ
ΠΏΠ΅ΡΠ΅ΡΡΡΠΎΠΉΠΊΠ°ΠΌΠΈ IGH ΠΈ Π±Π΅Π· t(11;14) ΠΈΠ»ΠΈ t(4;14) Π½Π΅ Π²ΡΡΠ²Π»ΡΠ»ΠΈ ΡΡΠ°Π½ΡΠ»ΠΎΠΊΠ°ΡΠΈΡ t(14;16) (q32;q23). Π£ 24 ΠΈΠ· 48 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ MM
(50%) ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ Π°Π½ΠΎΠΌΠ°Π»ΠΈΠΈ Ρ
ΡΠΎΠΌΠΎΡΠΎΠΌΡ 1. Π Π³ΡΡΠΏΠΏΠ΅ ΠΈΠ· 21 Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ del(13q14) Π² 15 ΡΠ»ΡΡΠ°ΡΡ
ΠΈΠΌΠ΅Π»ΠΈΡΡ ΠΏΠ΅ΡΠ΅ΡΡΡΠΎΠΉΠΊΠΈ IgH
Amp1q12;16. Π ΡΠΎ ΠΆΠ΅ Π²ΡΠ΅ΠΌΡ ΠΈΠ· 27 ΡΠ»ΡΡΠ°Π΅Π² Π±Π΅Π· del(13q14) Ρ 8 ΡΠΎΠ΄Π΅ΡΠΆΠ°Π»ΠΈΡΡ Amp1q12; Π² 13 ΡΠ»ΡΡΠ°ΡΡ
ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΈ ΠΏΠ΅ΡΠ΅ΡΡΡΠΎΠΉΠΊΠΈ
IgH. ΠΡΡΠ²Π»Π΅Π½Π° Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·Ρ ΠΌΠ΅ΠΆΠ΄Ρ del(13q14) ΠΈ Amp1q12(Ο2
= 8,26, p < 0,01) ΠΈ ΠΌΠ΅ΠΆΠ΄Ρ del(13q14) ΠΈ ΠΏΠ΅ΡΠ΅ΡΡΡΠΎΠΉΠΊΠ°ΠΌΠΈ IgH
(Ο2 = 3,88, p < 0,05). ΠΡΠ²ΠΎΠ΄Ρ: 13q Π΄Π΅Π»Π΅ΡΠΈΡ/ΠΌΠΎΠ½ΠΎΡΠΎΠΌΠΈΡ 13, ΠΏΠ΅ΡΠ΅ΡΡΡΠΎΠΉΠΊΡ IGH ΠΈ Π°Π½ΠΎΠΌΠ°Π»ΠΈΡ Ρ
ΡΠΎΠΌΠΎΡΠΎΠΌΡ 1 ΡΠ°ΡΡΠΎ ΠΎΡΠΌΠ΅ΡΠ°ΡΡ
ΠΏΡΠΈ MM, ΠΏΡΠΈΡΠ΅ΠΌ ΠΈΡ
ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π½Π΅ ΡΠ»ΡΡΠ°ΠΉΠ½ΠΎ ΠΈ ΡΠ΅ΡΠ½ΠΎ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·Π°Π½ΠΎ. ΠΠ½ΡΠ΅ΡΡΠ°Π·Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· FISH Π² ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Ρ
MACS Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ CD138-ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΡΡ
Π°Π½ΡΠΈΡΠ΅Π» ΡΠ²Π»ΡΠ΅ΡΡΡ Π²ΡΡΠΎΠΊΠΎΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π΄Π΅ΡΠ΅ΠΊΡΠΈΠΈ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΡ
ΡΠΈΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π°Π±Π΅ΡΡΠ°ΡΠΈΠΉ ΠΏΡΠΈ MM
Early Detection of t(8;21) Chromosomal Translocations During Treatment of PML-RARA Positive Acute Promyelocytic Leukemia: A Case Study
Here we describe a female patient who developed acute promyelocytic leukemia (APL) characterized by t(l5;17) translocation at diagnosis. The patient began treatment with all-trans retinoic acid (ATRA) + chemotherapy. During follow up, the patient was found to be negative for the t(15;17) transcript after 3 months of therapy which remained undetectable, thereafter. However, the emergence of a small clone with a t(8;21) abnormality was observed in the bone marrow and peripheral blood (PB) cells between 3 and 18 months following treatment initiation. The abnormal translocation observed in PB cells obtained at 3 months was detected after the second cycle of consolidation therapy and reappeared at 15 months during maintenance treatment, a period without ATRA. Although based on a single case, we conclude that genetic screening of multiple translocations in AML patients should be requested to allow early identification of other emerging clones during therapy that may manifest clinically following treatment
Distortion in a 7xxx aluminum alloy during liquid phase sintering
The distortion in a sintered 7xxx aluminum alloy, Al-7Zn-2.5Mg-1Cu (wt. pct), has been investigated by sintering three rectangular bars in each batch at 893 K (620 Β°C) for 0 to 40 minutes in nitrogen, followed by air or furnace cooling. They were placed parallel to each other, equally spaced apart at 2 mm, with their long axes being perpendicular to the incoming nitrogen flow. Pore evolution in each sample during isothermal sintering was examined metallographically. The compositional changes across sample mid-cross section and surface layers were analyzed using energy dispersive X-ray spectroscopy and X-ray photoelectron spectroscopy depth profiling, respectively. The two outer samples bent toward the middle one, while the middle sample was essentially distortion free after sintering. The distortion in the outer samples was a result of differential shrinkage between their outer and inner surfaces during isothermal sintering. The porous outer surface showed an enrichment of oxygen around the large pores as well as lower magnesium and zinc contents than the interior and inner surface of the same sample, while the inner surface was distinguished by the presence of AlN. The differential shrinkage was caused by different oxygen contents in local sintering atmosphere and unbalanced loss of magnesium and zinc between the outer and inner surfaces
Direct Measurements of the Branching Fractions for and and Determinations of the Form Factors and
The absolute branching fractions for the decays and
are determined using singly
tagged sample from the data collected around 3.773 GeV with the
BES-II detector at the BEPC. In the system recoiling against the singly tagged
meson, events for and events for decays are observed. Those yield
the absolute branching fractions to be and . The
vector form factors are determined to be
and . The ratio of the two form
factors is measured to be .Comment: 6 pages, 5 figure
Measurements of J/psi Decays into 2(pi+pi-)eta and 3(pi+pi-)eta
Based on a sample of 5.8X 10^7 J/psi events taken with the BESII detector,
the branching fractions of J/psi--> 2(pi+pi-)eta and J/psi-->3(pi+pi-)eta are
measured for the first time to be (2.26+-0.08+-0.27)X10^{-3} and
(7.24+-0.96+-1.11)X10^{-4}, respectively.Comment: 11 pages, 6 figure
BESII Detector Simulation
A Monte Carlo program based on Geant3 has been developed for BESII detector
simulation. The organization of the program is outlined, and the digitization
procedure for simulating the response of various sub-detectors is described.
Comparisons with data show that the performance of the program is generally
satisfactory.Comment: 17 pages, 14 figures, uses elsart.cls, to be submitted to NIM
Measurement of branching fractions for the inclusive Cabibbo-favored ~K*0(892) and Cabibbo-suppressed K*0(892) decays of neutral and charged D mesons
The branching fractions for the inclusive Cabibbo-favored ~K*0 and
Cabibbo-suppressed K*0 decays of D mesons are measured based on a data sample
of 33 pb-1 collected at and around the center-of-mass energy of 3.773 GeV with
the BES-II detector at the BEPC collider. The branching fractions for the
decays D+(0) -> ~K*0(892)X and D0 -> K*0(892)X are determined to be BF(D0 ->
\~K*0X) = (8.7 +/- 4.0 +/- 1.2)%, BF(D+ -> ~K*0X) = (23.2 +/- 4.5 +/- 3.0)% and
BF(D0 -> K*0X) = (2.8 +/- 1.2 +/- 0.4)%. An upper limit on the branching
fraction at 90% C.L. for the decay D+ -> K*0(892)X is set to be BF(D+ -> K*0X)
< 6.6%
Study of
New data are presented on from a sample of 58M
events in the upgraded BES II detector at the BEPC. There is a
conspicuous signal for and a peak at higher mass which
may be fitted with . From a combined analysis with
data, the branching ratio
is at the 95%
confidence level.Comment: 11 pages, 5 figures. Submitted to Phys. Lett.
Measurements of the Mass and Full-Width of the Meson
In a sample of 58 million events collected with the BES II detector,
the process J/ is observed in five different decay
channels: , , (with ), (with
) and . From a combined fit of all five
channels, we determine the mass and full-width of to be
MeV/ and
MeV/.Comment: 9 pages, 2 figures and 4 table. Submitted to Phys. Lett.
Search for the Lepton Flavor Violation Processes and
The lepton flavor violation processes and are
searched for using a sample of 5.8 events collected with
the BESII detector. Zero and one candidate events, consistent with the
estimated background, are observed in and
decays, respectively. Upper limits on the branching ratios are determined to be
and at the 90% confidence level (C.L.).Comment: 9 pages, 2 figure
- β¦